MedTrace Logo

Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer

NCT03932409 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this single arm, open label study is to evaluate the feasibility of pembrolizumab combined with radiation administered to the upper part of the vagina (vaginal cuff brachytherapy) followed by three cycles of pembrolizumab and chemotherapy in patients with endometrial cancer.

Conditions

Interventions

DRUG

Pembrolizumab

prior to VCB: 200mg IV given one week (7 days) before radiation after VCB: 200mg IV on day 1 of a 21 day cycle prior to chemotherapy

RADIATION

Vaginal cuff brachytherapy (VCB)

Treatment should commence within 12 weeks of the surgery/hysterectomy

DRUG

Paclitaxel

after VCB, Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles

DRUG

Carboplatin

after VCB, Carboplatin IV on day 1 of a 21 day cycle for 3 cycles

Sponsors & Collaborators

Principal Investigators

  • Christina Washington, MD · Stephenson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-19
Primary Completion
2025-09-25
Completion
2027-06-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03932409 on ClinicalTrials.gov